Kira Pharma
With over 30 years of experience in the medical and research realms, Dr. Jörg Köhl has been interested in the role of complement and other arms of innate immunity and the impact of this cross-talk on innate and adaptive immune responses. As Professor and Founding Director of the Institute for Systemic Inflammation Research, University of Lübeck (UzL), Germany, Dr. Köhl has successfully conducted numerous research studies and published almost 200 scientific research papers in reference to the complement therapeutic landscape with a focus on anaphylatoxic peptides C3a and C5a and their G-Protein-coupled receptors in experimental models of asthma, autoimmune diseases, transplantation and infections.
Dr. Köhl earned his undergraduate degree in the Study of Biology from Universities of Bochum and Mainz, alongside his medical degree from the University of Mainz, Germany.
This person is not in the org chart
This person is not in any offices
Kira Pharma
Kira Pharmaceuticals is a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases. Enabled by its proprietary LOGIC drug discovery platform, Kira is committed to advancing first-in-class and best-in-class therapies to patients around the world. The company is headquartered in Cambridge, Massachusetts with an R&D center in Suzhou, China.